References
Anagnostou, V., Niknafs, N., Marrone, K., Bruhm, D. C., White, J. R.,
Naidoo, J., Hummelink, K., Monkhorst, K., Lalezari, F., Lanis, M.,
Rosner, S., Reuss, J. E., Smith, K. N., Adleff, V., Rodgers, K.,
Belcaid, Z., Rhymee, L., Levy, B., Feliciano, J., … Velculescu,
V. E. (2020). Multimodal genomic features predict outcome of immune
checkpoint blockade in non-small-cell lung cancer. Nature Cancer, 1(1).
https://doi.org/10.1038/s43018-019-0008-8
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger,
A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F.,
Nakamura, Y., White, R., & Vogelstein, B. (1989). Chromosome 17
deletions and p53 gene mutations in colorectal carcinomas. Science (New
York, N.Y.), 244(4901). https://doi.org/10.1126/science.2649981
Bjorkman, P. J., Saper, M. A., Samraoui, B., Bennett, W. S., Strominger,
J. L., & Wiley, D. C. (1987). The foreign antigen binding site and T
cell recognition regions of class I histocompatibility antigens. Nature,
329(6139). https://doi.org/10.1038/329512a0
Campoli, M., & Ferrone, S. (2008). HLA antigen changes in malignant
cells: Epigenetic mechanisms and biologic significance. Oncogene,
27(45). https://doi.org/10.1038/onc.2008.273
Chan, T. A., Yarchoan, M., Jaffee, E., Swanton, C., Quezada, S. A.,
Stenzinger, A., & Peters, S. (2019). Development of tumor mutation
burden as an immunotherapy biomarker: Utility for the oncology clinic.
Annals of Oncology, 30(1), 44–56. https://doi.org/10.1093/annonc/mdy495
Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R.
M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N.,
Greenbaum, B., Carroll, J., Garon, E., Hyman, D. M., Zehir, A., Solit,
D., Berger, M., Zhou, R., Rizvi, N. A., & Chan, T. A. (2018). Patient
HLA class I genotype influences cancer response to checkpoint blockade
immunotherapy. Science, 359(6375), 582–587.
https://doi.org/10.1126/science.aao4572
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe,
D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G.
(2013). Sensitive detection of somatic point mutations in impure and
heterogeneous cancer samples. Nature Biotechnology, 31(3).
https://doi.org/10.1038/nbt.2514
Havel, J. J., Chowell, D., & Chan, T. A. (2019). The evolving landscape
of biomarkers for checkpoint inhibitor immunotherapy. Nature Reviews
Cancer, 19(3), 133–150. https://doi.org/10.1038/s41568-019-0116-x
Hellmann, M. D., Nathanson, T., Rizvi, H., Creelan, B. C., Sanchez-Vega,
F., Ahuja, A., Ni, A., Novik, J. B., Mangarin, L. M. B., Abu-Akeel, M.,
Liu, C., Sauter, J. L., Rekhtman, N., Chang, E., Callahan, M. K., Chaft,
J. E., Voss, M. H., Tenet, M., Li, X.-M., … Wolchok, J. D.
(2018). Genomic Features of Response to Combination Immunotherapy in
Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell, 33(5),
843-852.e4. https://doi.org/10.1016/j.ccell.2018.03.018
Hicklin, D. J., Marincola, F. M., & Ferrone, S. (1999). HLA class I
antigen downregulation in human cancers: T-cell immunotherapy revives an
old story. MOLECULAR MEDICINE TODAY, 5, 9.
Hiraki, A., Fujii, N., Murakami, T., Kiura, K., Aoe, K., Yamane, H.,
Masuda, K., Maeda, T., Sugi, K., Darzynkiewicz, Z., Tanimoto, M., &
Harada, M. (2004). High Frequency of Allele-specific Down-regulation of
HLA class I Expression in Lung Cancer Cell Lines. ANTICANCER RESEARCH,
4.
Keenan, T. E., Burke, K. P., & Van Allen, E. M. (2019). Genomic
correlates of response to immune checkpoint blockade. Nature Medicine,
25(3), 389–402. https://doi.org/10.1038/s41591-019-0382-x
Klein, J., & Sato, A. (2000). The HLA system. First of two parts. The
New England Journal of Medicine, 343(10).
https://doi.org/10.1056/NEJM200009073431006
Lan, S., Li, H., Liu, Y., Ma, L., Liu, X., Liu, Y., Yan, S., & Cheng,
Y. (2019). Somatic mutation of LRP1B is associated with tumor
mutational burden in patients with lung cancer. Lung Cancer (Amsterdam,
Netherlands), 132. https://doi.org/10.1016/j.lungcan.2019.04.025
Li, J., Lupat, R., Amarasinghe, K. C., Thompson, E. R., Doyle, M. A.,
Ryland, G. L., Tothill, R. W., Halgamuge, S. K., Campbell, I. G., &
Gorringe, K. L. (2012). CONTRA: copy number analysis for targeted
resequencing. Bioinformatics (Oxford, England), 28(10).
https://doi.org/10.1093/bioinformatics/bts146
Malekzadeh, P., Pasetto, A., Robbins, P. F., Parkhurst, M. R., Paria, B.
C., Jia, L., Gartner, J. J., Hill, V., Yu, Z., Restifo, N. P., Sachs,
A., Tran, E., Lo, W., Somerville, R. P., Rosenberg, S. A., & Deniger,
D. C. (2019). Neoantigen screening identifies broad TP53 mutant
immunogenicity in patients with epithelial cancers. The Journal of
Clinical Investigation, 129(3). https://doi.org/10.1172/JCI123791
Malumbres, M., & Barbacid, M. (2003). RAS oncogenes: The first 30
years. Nature Reviews. Cancer, 3(6). https://doi.org/10.1038/nrc1097
McGranahan, N., Rosenthal, R., Hiley, C. T., Rowan, A. J., Watkins, T.
B. K., Wilson, G. A., Birkbak, N. J., Veeriah, S., Van Loo, P., Herrero,
J., Swanton, C., Swanton, C., Jamal-Hanjani, M., Veeriah, S., Shafi, S.,
Czyzewska-Khan, J., Johnson, D., Laycock, J., Bosshard-Carter, L.,
… Dessimoz, C. (2017). Allele-Specific HLA Loss and Immune Escape
in Lung Cancer Evolution. Cell, 171(6), 1259-1271.e11.
https://doi.org/10.1016/j.cell.2017.10.001
Mehta, A. M., Jordanova, E. S., Kenter, G. G., Ferrone, S., & Fleuren,
G.-J. (2007). Association of antigen processing machinery and HLA class
I defects with clinicopathological outcome in cervical carcinoma. Cancer
Immunology, Immunotherapy, 57(2), 197–206.
https://doi.org/10.1007/s00262-007-0362-8
Montesion, M., Murugesan, K., Jin, D. X., Sharaf, R., Sanchez, N.,
Guria, A., Minker, M., Li, G., Fisher, V., Sokol, E. S., Pavlick, D. C.,
Moore, J. A., Braly, A., Singal, G., Fabrizio, D., Comment, L. A.,
Rizvi, N. A., Alexander, B. M., Frampton, G. M., … Albacker, L.
A. (2020). Somatic HLA class I loss is a widespread mechanism of immune
evasion which refines the use of tumor mutational burden as a biomarker
of checkpoint inhibitor response. Cancer Discovery, CD-20-0672.
https://doi.org/10.1158/2159-8290.CD-20-0672
Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hostetter,
R., Cleary, K., Bigner, S. H., Davidson, N., Baylin, S., & Devilee, P.
(1989). Mutations in the p53 gene occur in diverse human tumour types.
Nature, 342(6250). https://doi.org/10.1038/342705a0
Parham, P., Benjamin, R. J., Chen, B. P., Clayberger, C., Ennis, P. D.,
Krensky, A. M., Lawlor, D. A., Littman, D. R., Norment, A. M., & Orr,
H. T. (1989). Diversity of class I HLA molecules: Functional and
evolutionary interactions with T cells. Cold Spring Harbor Symposia on
Quantitative Biology. https://doi.org/10.1101/sqb.1989.054.01.063
Parham, P., & Ohta, T. (1996). Population biology of antigen
presentation by MHC class I molecules. Science (New York, N.Y.),
272(5258). https://doi.org/10.1126/science.272.5258.67
Rizvi, H., Sanchez-Vega, F., La, K., Chatila, W., Jonsson, P., Halpenny,
D., Plodkowski, A., Long, N., Sauter, J. L., Rekhtman, N., Hollmann, T.,
Schalper, K. A., Gainor, J. F., Shen, R., Ni, A., Arbour, K. C.,
Merghoub, T., Wolchok, J., Snyder, A., … Hellmann, M. D. (2018).
Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1
and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With
Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation
Sequencing. Journal of Clinical Oncology, 36(7), 633–641.
https://doi.org/10.1200/JCO.2017.75.3384
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen,
R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro,
A., Kaley, T. J., Kendall, S. M., Motzer, R. J., Hakimi, A. A., Voss, M.
H., Russo, P., Rosenberg, J., Iyer, G., Bochner, B. H., … Morris,
L. G. T. (2019). Tumor mutational load predicts survival after
immunotherapy across multiple cancer types. Nature Genetics, 51(2),
202–206. https://doi.org/10.1038/s41588-018-0312-8
Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La,
K. C., Dimitriadoy, S., Liu, D. L., Kantheti, H. S., Saghafinia, S.,
Chakravarty, D., Daian, F., Gao, Q., Bailey, M. H., Liang, W.-W., Foltz,
S. M., Shmulevich, I., Ding, L., Heins, Z., … Schultz, N. (2018).
Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell, 173(2).
https://doi.org/10.1016/j.cell.2018.03.035
Shim, J. H., Kim, H. S., Cha, H., Kim, S., Kim, T. M., Anagnostou, V.,
Choi, Y.-L., Jung, H. A., Sun, J.-M., Ahn, J. S., Ahn, M.-J., Park, K.,
Park, W.-Y., & Lee, S.-H. (2020). HLA-corrected tumor mutation burden
and homologous recombination deficiency for the prediction of response
to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.
Annals of Oncology, 31(7), 902–911.
https://doi.org/10.1016/j.annonc.2020.04.004
Shukla, S. A., Rooney, M. S., Rajasagi, M., Tiao, G., Dixon, P. M.,
Lawrence, M. S., Stevens, J., Lane, W. J., Dellagatta, J. L., Steelman,
S., Sougnez, C., Cibulskis, K., Kiezun, A., Hacohen, N., Brusic, V., Wu,
C. J., & Getz, G. (2015). Comprehensive analysis of cancer-associated
somatic mutations in class I HLA genes. Nature Biotechnology, 33(11).
https://doi.org/10.1038/nbt.3344
Stracquadanio, G., Wang, X., Wallace, M. D., Grawenda, A. M., Zhang, P.,
Hewitt, J., Zeron-Medina, J., Castro-Giner, F., Tomlinson, I. P.,
Goding, C. R., Cygan, K. J., Fairbrother, W. G., Thomas, L. F., Sætrom,
P., Gemignani, F., Landi, S., Schuster-Böckler, B., Bell, D. A., &
Bond, G. L. (2016). The importance of p53 pathway genetics in inherited
and somatic cancer genomes. Nature Reviews. Cancer, 16(4).
https://doi.org/10.1038/nrc.2016.15
Thielens, A., Vivier, E., & Romagné, F. (2012). NK cell MHC class I
specific receptors (KIR): From biology to clinical intervention. Current
Opinion in Immunology, 24(2), 239–245.
https://doi.org/10.1016/j.coi.2012.01.001
Wade, M., Li, Y.-C., & Wahl, G. M. (2013). MDM2, MDMX and p53 in
oncogenesis and cancer therapy. Nature Reviews Cancer, 13(2), 83–96.
https://doi.org/10.1038/nrc3430
Wang, L., Yan, K., He, X., Zhu, H., Song, J., Chen, S., Cai, S., Zhao,
Y., & Wang, L. (2021). LRP1B or mutations are associated with
higher tumor mutational burden and worse survival in hepatocellular
carcinoma. Journal of Cancer, 12(1). https://doi.org/10.7150/jca.48983